RNAZ TransCode Therapeutics

TransCode Therapeutics Retains Tungsten Advisors for Strategic Process on TTX-MC138

TransCode Therapeutics has engaged Tungsten Advisors to lead a formal strategic review. The process will evaluate licensing, development partnerships, asset sales, and other transactions for TTX-MC138 and the oncology portfolio. No specific transaction has been agreed and the company will not update unless a deal is approved.

TransCode to Present TTX-MC138 Phase 1a Data at ESMO Congress 2026

TransCode Therapeutics will present updated Phase 1a clinical data for TTX-MC138 (an antagomiR targeting miR-10b) in patients with advanced solid tumors at the ESMO Congress 2026 on October 23. The poster is titled "Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors." This is a data presentation at a major oncology conference.

TransCode Therapeutics partners with Natera on Phase 2a TTX-MC138 trial in MRD+ CRC

TransCode Therapeutics entered a collaboration with Natera to use Signatera MRD testing to identify and enroll MRD-positive colorectal cancer patients (post-curative therapy, imaging-negative) into the ongoing Phase 2a trial of TTX-MC138. The trial is conducted under the PRE-I-SPY platform (NCT05868226) and targets an unmet need in MRD-positive patients with no approved therapies.

TransCode TTX-MC138 Phase 1a reports 71.4% stable disease, durable control in advanced solid tumors

Updated Phase 1a data show 71.4% stable disease rate, 57.1% disease control at 3 months, 35.7% at 6 months, and 3 patients progression-free at 12 months in heavily pretreated patients. Primary safety endpoint met with no dose-limiting toxicities. Exploratory biomarkers support antitumor immune activation.

TransCode (RNAZ) Receives Patent Allowances in Australia and Japan for RNA Immuno-Oncology Platform

TransCode received a Notice of Acceptance in Australia for a patent covering siRNA-loaded iron-oxide nanoparticles for immune checkpoint inhibition in multiple cancers, and a Notice of Allowance (now granted as JP 7886877) in Japan for RNA oligonucleotides that activate RIG-I in miR-21 expressing tumors. These strengthen the company's global IP position but do not alter any regulatory or clinical milestone for its therapeutic candidates.

TransCode submits IND amendment for TTX-MC138 Phase 2a in colorectal cancer

TransCode and Quantum Leap submitted an IND amendment to the FDA for a Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer patients with positive ctDNA after curative therapy. The trial will enroll up to 45 patients and is planned to begin in the first half of 2026 under the PRE-I-SPY platform.